Prescription drug · NDA
Brinsupri (brensocatib) NDC 71558-002
Brensocatib 25 mg/1 · Tablet · Oral · Insmed Incorporated
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 71558-002-30 | 71558000230 | 30 TABLET in 1 BOTTLE (71558-002-30)Marketed from Aug 12, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Brinsupri
- Generic name (nonproprietary)
- brensocatib
- Active ingredients
- Brensocatib — 25 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- Insmed Incorporated
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 217673
- Marketing start
- Listing expires
- Identifiers
- Product ID 71558-002_43046e5b-e40b-423d-a98d-a2fecc2cbd2eSPL ID 43046e5b-e40b-423d-a98d-a2fecc2cbd2eSPL set ID b56986ae-e7db-421e-b622-a7f41e321f3dRxCUI 2721885, 2721891, 2721893, 2721895UNII 25CG88L0BB
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N471558000230followed by a unit qualifier and the quantityPackage 71558-0002-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older. BRINSUPRI is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the treatment of non-cystic fibrosis bronchiectasis in adult and pediatric patients 12 years of age and older. ( 1 )
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 217673
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Brinsupribrensocatib | Brensocatib 10 mg/1 | TabletOral | Insmed Incorporated | 71558-001 |